IGC

NYSEAMERICAN 已收盘

IGC Pharma, Inc.

0.25 USD
-0.00+1.18%
2026-08-03
市值
$24.82M
市盈率
EPS
-0.08
股息率
52 周区间
0.24 – 0.50
成交量
307.70K
Beta
0.46
目标价
4.25
52W 低 0.2452W 高 0.50
价格走势

公司简介

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare provi...